Study of the effects of immunosuppressive agents on human islet cells in vitro

National Medical Journal of China

Volumn 85, Issue 10, 2005, Pages 654-656

  Cai, Jin Quan ^a   Tan, Jian Ming ^b   Dong, Wei Ping ^b   Wang, Yu Fei ^b   Wang, Jian Bo ^b  

^a FUZHOU GENERAL HOSPITAL   (China)

^b NONE

Author keywords

Immunosuppression; Islet, transplantation

Indexed keywords

ENZYME; FICOLL; FINGOLIMOD; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ARTICLE; CELL DAMAGE; CELL ISOLATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RELEASE; LOW DRUG DOSE; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PURIFICATION;

CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS; PROPYLENE GLYCOLS; SIROLIMUS; SPHINGOSINE; TACROLIMUS;

EID: 15844381342     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ricordi C, Tzakis AG, Carroll PB, et al. Human islet isolation and allotransplanta -tion in 22 consecutive cases. Transplantation, 1992, 53:407-414.
2. Federlin KF, Hering B, Bretzel RG. Islet transplantation: Clinical and experimental. Horm Metab Res Suppl, 1992,26:148-151.
3. Vorgars F, Vives-Pi M, Somoza N, et al. Advantage of using a cell separator and metrizamide gradients for human islet purification. Transplantation, 1996,61: 1562-1566.
4. Robertson RP, Davis C, Larsen J, et al. Pancreas and islet transplantation for patients with diabetes. Diabetes Care, 2000,23: 112-116.
5. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med, 2000,343:230-238.
6. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes,1988;37:413-420.
7. Shapio AM, Gallant H, Hao E, et al. Portal vein immunosuppressant levels and islet graft toxicity. Transplant Proc, 1998,30:641.
8. 2+ levels in insulin-secreting cell. Biochem Pharmacol, 2000,59:545-556.
9. Herold KC, Nagamatsu S, Buse JB, et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Trans -plantation, 1993,55:186-192.
10. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allogrft biopsies and clinical correlation. Transplantation, 1999,68:369-402.
11. Kneteman NM, Lakey JR, Wagner T, et al. Beneficial metabolic impact of the novel immunosuppresant rapamycin in chronic canine islet autograft recipients. Transplant Proc, 1995,27:3213.
12. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion. J Immunol, 2000,164:5761-5770.
13. Suzuki S, Enosawa S, Kakefuda T, et al. Immunosuppressive effect of a new drug, FTY720, on lymphocyte respones in vitro and cardiac allograft survival in rats. Transpl Immunol, 1996,4:252-255.
14. Fu F, Hu S, Li S, et al. FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. Transplant Proc, 2001,33:672-673.